Advertisement
Table 4 Multivariate analysis of overall expenditure for diagnosis and treatment of 2356 patients with colorectal cancer
| Characteristic | Estimate (95% CI) | P |
|---|---|---|
| Intercept | 10.4 (10.2, 10.5) | <0.001 |
| Hospital type (Ref = general) | ||
| Specialized | 0.2 (0.1, 0.2) | <0.001 |
| Age at diagnosis (years) (Ref = ≥65) | ||
| <45 | 0.0 (−0.1, 0.1) | 0.419 |
| 45–54 | 0.1 (0.0, 0.2) | 0.131 |
| 55–64 | 0.0 (−0.1, 0.1) | 0.522 |
| Sex (Ref = women) | ||
| Men | 0.0 (−0.1, 0.1) | 0.969 |
| Education (Ref = primary school or below) | ||
| Junior high school | 0.0 (−0.1, 0.1) | 0.815 |
| Senior high school | 0.0 (0.0, 0.1) | 0.310 |
| Undergraduate or higher | 0.1 (0, 0.2) | 0.134 |
| Occupation (Ref = self-employee or unemployee) | ||
| Farmer | 0.0 (−0.1, 0.2) | 0.493 |
| Enterprise or company employee/worker | −0.1 (−0.2, 0.0) | 0.057 |
| Retiree | 0.1 (−0.1, 0.2) | 0.377 |
| Public sector employee | 0.2 (0.1, 0.3) | 0.004 |
| Other | 0.0 (−0.3, 0.2) | 0.778 |
| Healthcare insurance type (Ref = new rural cooperative medical scheme) | ||
| Urban employee basic medical insurance | 0.0 (−0.1, 0.1) | 0.641 |
| Urban resident basic medical insurance | 0.0 (−0.1, 0.1) | 0.707 |
| Commercial insurance | 0.0 (−0.3, 0.4) | 0.792 |
| Self-paid | 0.0 (−0.2, 0.2) | 0.905 |
| Other | 0.4 (0.1, 0.7) | 0.020 |
| Previous-year household income (CNY) (Ref = ≤20,000) | ||
| 20,000–39,999 | 0.1 (0.0, 0.2) | 0.006 |
| 40,000–69,999 | 0.1 (0.0, 0.2) | 0.046 |
| ≥70,000 | 0.1 (0.0, 0.2) | 0.006 |
| Clinical stage (Ref = I) | ||
| II | 0.0 (−0.1, 0.1) | 0.822 |
| III | 0.1 (0.0, 0.2) | 0.099 |
| IV | 0.3 (0.1, 0.4) | <0.001 |
| Pathologic type (Ref = others) | ||
| Adenocarcinoma | 0.2 (0.1, 0.3) | <0.001 |
| Therapeutic regimen (Ref = surgery) | ||
| Chemotherapy | 0.2 (0.1, 0.3) | <0.001 |
| Surgery and postoperative chemotherapy | 0.2 (0.1, 0.3) | <0.001 |
| Symptomatic treatment | 0.1 (0.0, 0.2) | 0.170 |
| Concurrent chemoradiotherapy | 0.8 (0.6, 1.0) | <0.001 |
| Radiotherapy | 0.5 (0.3, 0.7) | <0.001 |
| Neoadjuvant chemotherapy and surgery | 0.2 (−0.2, 0.6) | 0.251 |
